The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer-Reference-Cited by-同舟云学术

The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Published:2014-05-07 Issue:1 Volume:7 Page:
ISSN:1757-2215
Container-title:Journal of Ovarian Research
language:en
Short-container-title:J Ovarian Res

Author:

Kobayashi Masanori,Chiba Asako,Izawa Hiromi,Yanagida Eri,Okamoto Masato,Shimodaira Shigetaka,Yonemitsu Yoshikazu,Shibamoto Yuta,Suzuki Noboru,Nagaya Masaki,

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynaecology,Oncology

Link

https://link.springer.com/content/pdf/10.1186/1757-2215-7-48.pdf

Reference34 articles.

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10–29. 10.3322/caac.20138

2. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006,95(Suppl 1):S161-S192.

3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20: 1248–1259. 10.1200/JCO.20.5.1248

4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2003, 21: 3194–3200. 10.1200/JCO.2003.02.153

5. Hall M, Rustin G: Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep 2011, 13: 459–471. 10.1007/s11912-011-0199-3

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed-Type Hypersensitivity: An Excellent Indicator of Anti-tumor Immunity With Wilms' Tumor 1 (WT1) Dendritic Cell Vaccine Therapy;Cureus;2023-11-22

2. Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape;Pharmaceuticals;2023-07-24

3. Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics;Immunotherapy;2023-04

4. Immunotherapy in gynecologic malignancies;DiSaia and Creasman Clinical Gynecologic Oncology;2023

5. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation;Nature Reviews Cancer;2022-09-15